Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has earned a consensus rating of "Buy" from the six research firms that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $8.00.
A number of equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. JMP Securities reiterated a "market outperform" rating and set a $5.00 price target on shares of Sana Biotechnology in a report on Tuesday, June 24th. Finally, Morgan Stanley assumed coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price for the company.
View Our Latest Report on SANA
Sana Biotechnology Stock Up 6.6%
NASDAQ:SANA traded up $0.21 during mid-day trading on Monday, hitting $3.32. 5,981,549 shares of the stock traded hands, compared to its average volume of 5,987,964. The business's 50-day moving average price is $3.52 and its 200 day moving average price is $2.69. The company has a market cap of $747.47 million, a PE ratio of -3.13 and a beta of 1.90. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. Analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sana Biotechnology
Several institutional investors and hedge funds have recently modified their holdings of SANA. Cerity Partners LLC bought a new stake in shares of Sana Biotechnology during the fourth quarter valued at approximately $25,000. Tower Research Capital LLC TRC grew its holdings in shares of Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after purchasing an additional 10,548 shares in the last quarter. Syon Capital LLC purchased a new position in shares of Sana Biotechnology in the fourth quarter valued at $27,000. Ameriprise Financial Inc. purchased a new position in shares of Sana Biotechnology in the fourth quarter valued at $29,000. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Sana Biotechnology in the first quarter valued at $29,000. Institutional investors own 88.23% of the company's stock.
About Sana Biotechnology
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Further Reading
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access